TELA Bio, Inc. (NASDAQ: TELA) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.18 million.

GUIDANCE:

TELA Bio, Inc. sees Q1 2023 revenue of $60-65 million, versus the consensus of $59.6 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.